FDC documents library
Recent additions to F-D-C Reports' document library include the Senate Finance Committee FDL-1letter to drug companies seeking information on educational grants, the HHS FDL-2Inspector General Office letter to Senate Health Committee Chairman Mike Enzi (R-Wyo.) regarding personal conduct allegations about FDA Commissioner nominee Lester Crawford, a federal FDL-3Appeals Court ruling and FDL-4District Court ruling on "authorized" generics in Teva v. Crawford, and FDA's letter approving FDL-5Pfizer's Revatio for pulmonary arterial hypertension to improve exercise ability. Sign up for a free twice-monthly email alert to new documents at 1http://www.fdcreports.com/documentsalert and browse documents at 2http://www.fdcreports.com/documents...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.